Overall, the results of the CALGB-RATIFY trial were practice changing, showing that younger adults with newly diagnosed AML and an FLT3 mutation had a 22% lower risk of death with the addition of midostaurin to standard chemotherapy. The gene discussed is FLT3; the disease is acute myeloid leukemia.